ArticleHemaSphere2024

Robust and cost-effective CRISPR/Cas9 gene editing of primary tumor B cells in Eµ-TCL1 model of chronic lymphocytic leukemia.

Rosita Del Prete et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.